 |
|
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George
Clin Mol Hepatol. 2024;30(3):436-448. Published online 2024 Apr 16 DOI: https://doi.org/10.3350/cmh.2024.0109
|
|
Citations to this article as recorded by
 Association of the Number of Concurrent Metabolic Syndrome Risk Factors with Textbook Outcomes Following Liver Resection for Patients with Hepatocellular Carcinoma: A Multicenter Study
Zhan-Cheng Qiu, Jun-Long Dai, Yu Zhang, Fei Xie, Yu Yu, Shu-Sheng Leng, Tian-Fu Wen, Chuan Li
Annals of Surgical Oncology.2025; 32(1): 399. CrossRef Deciphering the roles of neddylation modification in hepatocellular carcinoma: Molecular mechanisms and targeted therapeutics
Wenxin Wu, Xuanyi Wang, Ruijie Ma, Shuhong Huang, Hongguang Li, Xinxing Lyu
Genes & Diseases.2025; 12(4): 101483. CrossRef Alterations of Krüppel-like Factor Signaling and Potential Targeted Therapy for Hepatocellular Carcinoma
Rongfei Fang, Chunxiu Sha, Qun Xie, Dengfu Yao, Min Yao
Anti-Cancer Agents in Medicinal Chemistry.2025; 25(2): 75. CrossRef Associations of MAFLD subtypes and air pollutants with multi-system morbidity and all-cause mortality: A prospective cohort study
Jingyi Zhang, Shanshan Ran, Shengtao Wei, Fei Tian, Lan Chen, Zijun Yang, Ge Chen, Hualiang Lin
Ecotoxicology and Environmental Safety.2025; 291: 117893. CrossRef Global burden and international disparities in NASH-associated liver Cancer: mortality trends (1990–2021) and future projections to 2045
Qilong Nie, Yongwen Jiang, Mingyang Li, Qiuyan Liang, Xiaoai Mo, Tengyu Qiu, Qunfang Jiang, Kaizhou Huang, Youqing Xie, Ying Chen, Xiaojun Ma, Jianhong Li, Kaiping Jiang
Frontiers in Public Health.2025;[Epub] CrossRef Exploring emerging frontiers in hepatology: iLIVER's continuing journey
Ming-Da Wang, Xin-Fei Xu, Lei Cai, Tian Yang
iLIVER.2025; 4(1): 100148. CrossRef A review of image guidance and localization methods for liver puncture robots
Yongde Zhang, Jiabin Yang, Xuequan Huang, Chuang He
Journal of Robotic Surgery.2025;[Epub] CrossRef Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
Liver International.2025;[Epub] CrossRef Splanchnic inflammatory syndrome and the not-so-silent risk of cancer
Richard C Semelka MD, Miguel Ramalho MD
Gastroenterology & Hepatology: Open access.2024; 15(3): 63. CrossRef Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c
Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
Clinical and Molecular Hepatology.2024; 30(4): 705. CrossRef Unraveling the epidemiology of metabolic dysfunction-associated liver cancer: Insights from mixed etiologies, regional variations, and gender disparities
Gong Feng, Ya-Fei Fan, Ru-Xin Li, Giovanni Targher, Christopher D. Byrne, Ming-Hua Zheng
iLIVER.2024; 3(3): 100113. CrossRef Impact of occult hepatitis B virus infection and high-fat diet on hepatocellular carcinoma development
Kun Chen, Chunfeng Qu
Hepatoma Research.2024;[Epub] CrossRef Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George
Hepatology International.2024; 18(6): 1740. CrossRef Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A sy
Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li
Clinical and Molecular Hepatology.2024; 30(4): 965. CrossRef Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis
Muhammed Shabil, Mahalaqua Nazli Khatib, Suhas Ballal, Pooja Bansal, Balvir S. Tomar, Ayash Ashraf, M. Ravi Kumar, Aashna Sinha, Pramod Rawat, Abhay M. Gaidhane, Sanjit Sah, Afukonyo Shidoiku Daniel, Ambanna Yappalparvi, Ganesh Bushi
BMC Endocrine Disorders.2024;[Epub] CrossRef APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin, Haitao Zhao, Motoyuki Otsuka, Sadahisa Ogasawara, Jacob George, Pierce K. H. Chow, Jianqiang Cai, Shuichiro Shiina, Naoya Kato, Osamu Yokosuka, Kyoko Oura, Thomas Yau, Stephen L. Chan, Min
Hepatology International.2024; 18(6): 1661. CrossRef
|